InvestorsHub Logo
Followers 36
Posts 1736
Boards Moderated 0
Alias Born 05/13/2011

Re: None

Sunday, 01/31/2016 10:19:18 AM

Sunday, January 31, 2016 10:19:18 AM

Post# of 106
Vical is working on a dengue treatment. However the company is faced hardship with other pipeline ventures.
Don't know if they will jump into zika territory

From vicals website:

"Tetravalent dengue vaccine (TVDV) is a plasmid DNA-based infectious disease vaccine in clinical development in humans for the prevention of all 4 dengue virus serotypes. Vical manufactured TVDV under contract with the Naval Medical Research Center, who has conducted Phase 1 testing of this vaccine. TVDV utilizes Vical’s proprietary adjuvant formulation, Vaxfectin®, to increase immune responses."

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.